Inmune Bio earnings were -$40.8M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest INMB earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$9.7M, up 5.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, INMB reported annual earnings of -$42.1M, with 40.2% growth.
Inmune Bio (NASDAQ: INMB) reported Q1 2025 earnings per share (EPS) of -$0.43, up 29.51% year over year. Total INMB earnings for the quarter were -$9.74 million. In the same quarter last year, Inmune Bio's earnings per share (EPS) was -$0.61.
As of the last Inmune Bio earnings report, Inmune Bio is currently losing money. Inmune Bio's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$40.80 million, a 18.26% increase year over year.
What was INMB's earnings growth in the past year?
As of Inmune Bio's earnings date in Q3 2025, Inmune Bio's earnings has grown year over year. INMB earnings in the past year totalled -$40.80 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.